4 results
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
The primary endpoint of this feasibility study is the technical success of positioning the SLIDE device to verify the speed and ease of use without unexpected device related adverse events. A technical success is defined that the SLIDE device was…
The primary goal of this study is to describe possible causes of gait asymmetry in patients with an endoprosthetic reconstruction of the knee joint due to a bone tumour. Therefore, the assumed gait asymmetry is first verified (part A). Subsequently…
The objective of this study is to demonstrate that use of the Sentinel® Cerebral Protection System significantly reduces the risk of periproceduralstroke (*72 hours) after transcatheter aortic valve replacement (TAVR).